Drug intelligence / Profile preview

C4X3256

Development stage
Discontinued
Lead developer
Indivior
Modality
Small Molecules
Administration
Oral
01

Overview

C4X3256 is an investigational, oral, small-molecule, highly-selective antagonist of the orexin 1 receptor (OX1R). It was originally developed by C4X Discovery and is now licensed and clinically developed by Indivior. Its primary mechanism is selective blockade of OX1R in the central nervous system, a pathway shown to mediate craving and relapse behaviors associated with substance use disorders, notably opioid use disorder (OUD). Preclinical data demonstrated efficacy in animal models of opioid, nicotine, and cocaine addiction, reducing drug-seeking and relapse behaviors. Unlike opioid-based therapies, C4X3256 is non-opioid and does not act on opioid receptors. It is currently in phase 2 clinical development for opioid use disorder, supported by a U.S. National Institutes of Health (NIH) HEAL grant.

Other names
[14C]-IDV184001AN
02

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on C4X3256.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C4X3256.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call